# SAM #ARPA-H-SOL-26-165

ARPA-H COSMOS Initiative: Organ System Modeling and Drug Screening in Microgravity

**Buyer:** ARPA-H
**Posted:** September 16, 2026
**Respond By:** October 07, 2026
**Identifier:** ARPA-H-SOL-26-165
**NAICS:** 541714, 541715, 927110

ARPA-H, a division of the National Institutes of Health under the Department of Health and Human Services, is seeking innovative research and development solutions for the Comprehensive Organ System Modeling in Outer Space (COSMOS) Initiative.
- Government Buyer:
  - Advanced Research Projects Agency for Health (ARPA-H)
  - National Institutes of Health (NIH)
  - Department of Health and Human Services (HHS)
- Opportunity Focus:
  - Research and development services for organ system modeling and drug screening in microgravity
  - Investigate whether microgravity in Low Earth Orbit accelerates tissue aging across organ types and age groups
  - If successful, establish a platform for autonomous, high-throughput drug screening in space
- Anticipated Outcomes:
  - Faster and more cost-effective drug research and development compared to Earth-based methods
  - Multiple Other Transaction awards expected
- Requirements:
  - Proposals must address organ system modeling and drug screening in microgravity
  - No specific products, part numbers, or purchase quantities listed
- OEMs and Vendors:
  - No OEMs or vendors are named in the solicitation
- Unique/Notable Requirements:
  - Focus on innovative, autonomous solutions for drug screening in space
  - Emphasis on high-throughput capabilities and tissue aging research
- Interested parties should review attached documents for further technical and submission details.

### Description

<p>The Advanced Research Projects Agency for Health (ARPA-H) Comprehensive Organ System Modeling in Outer Space (COSMOS) Initiative aims to definitively prove or disprove if exposure to microgravity in Low Earth Orbit (LEO) truly accelerates tissue aging across brain, cardiac, uterine, and kidney tissue types and across several adult age brackets. Provided Tissue Aging Rate in Space (TARIS) exceeds Tissue Aging Rate on Earth (TAROE) at a rate that exceeds the on Earth breakeven cost for new drug R&amp;D, COSMOS will create a first-in-class platform for fully autonomous, high-throughput drug screening in LEO that would be more cost effective and faster than new drug R&amp;D on Earth.</p>

<p>ARPA-H anticipates multiple Other Transaction awards resulting from this announcement.</p>

<p>Interested parties are invited to download and review the attached COSMOS Innovative Solutions Opening (ISO) ARPA-H-SOL-26-165</p>

[View original listing](https://sam.gov/opp/f7ed4368bf8c48e39ca45d3204830c25/view)